Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications - PubMed (original) (raw)
Review
Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications
Ravi Varadhan et al. Med Care. 2010 Jun.
Abstract
Background: An evaluation of the effect of a healthcare intervention (or an exposure) must consider multiple possible outcomes, including the primary outcome of interest and other outcomes such as adverse events or mortality. The determination of the likelihood of benefit from an intervention, in the presence of other competing outcomes, is a competing risks problem. Although statistical methods exist for quantifying the probability of benefit from an intervention while accounting for competing events, these methods have not been widely adopted by clinical researchers.
Objectives: (1) To demonstrate the importance of considering competing risks in the evaluation of treatment effectiveness, and (2) to review appropriate statistical methods, and recommend how they might be applied.
Research design and methods: We reviewed 3 statistical approaches for analyzing the competing risks problem: (a) cause-specific hazard (CSH), (b) cumulative incidence function (CIF), and (c) event-free survival (EFS). We compare these methods using a simulation study and a reanalysis of a randomized clinical trial.
Results: Simulation studies evaluating the statistical power to detect the effect of intervention under different scenarios showed that: (1) CSH approach is best for detecting the effect of an intervention if the intervention only affects either the primary outcome or the competing event; (2) EFS approach is best only when the intervention affects both primary and competing events in the same manner; and (3) CIF approach is best when the intervention affects both primary and competing events, but in opposite directions. Using data from a randomized controlled trial, we demonstrated that a comprehensive approach using all 3 approaches provided useful insights on the effect of an intervention on the relative and absolute risks of multiple competing outcomes.
Conclusions: CSH is the fundamental measure of outcome in competing risks problems. It is appropriate for evaluating treatment effects in the presence of competing events. Results of CSH analysis for primary and competing outcomes should always be reported even when EFS or CIF approaches are called for. EFS is appropriate for evaluating the composite effect of an intervention, only when combining different endpoints is clinically and biologically meaningful, and the treatment has similar effects on all event types. CIF is useful for evaluating the likelihood of benefit from an intervention over a meaningful period. CIF should be used for absolute risk calculations instead of the widely used complement of the Kaplan-Meier (1 - KM) estimator.
Similar articles
- Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
Rauch G, Kieser M, Ulrich S, Doherty P, Rauch B, Schneider S, Riemer T, Senges J. Rauch G, et al. Eur J Prev Cardiol. 2014 Jan;21(1):74-80. doi: 10.1177/2047487312460518. Epub 2012 Sep 10. Eur J Prev Cardiol. 2014. PMID: 22964966 - Cumulative incidence in competing risks data and competing risks regression analysis.
Kim HT. Kim HT. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):559-65. doi: 10.1158/1078-0432.CCR-06-1210. Clin Cancer Res. 2007. PMID: 17255278 - "Just Another Statistic".
Machtay M, Glatstein E. Machtay M, et al. Oncologist. 1998;3(3):III-IV. Oncologist. 1998. PMID: 10388105 - Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Alexander KP, et al. Circulation. 2007 May 15;115(19):2549-69. doi: 10.1161/CIRCULATIONAHA.107.182615. Circulation. 2007. PMID: 17502590 Review. - Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M, Walker-Corkery E, Barry MJ. McNaughton-Collins M, et al. J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016. J Natl Cancer Inst Monogr. 2004. PMID: 15504921 Review.
Cited by
- Weighing risks and benefits in the presence of competing risks.
Lesko CR, Zalla LC, Heyward J, Joseph C, Edwards JK. Lesko CR, et al. Curr Epidemiol Rep. 2023 Dec;10(4):221-239. doi: 10.1007/s40471-023-00331-1. Epub 2023 Sep 22. Curr Epidemiol Rep. 2023. PMID: 39473700 Free PMC article. - Statistical Power and Performance of Strategies to Analyze Composites of Survival and Duration of Ventilation in Clinical Trials.
Chen Z, Harhay MO, Fan E, Granholm A, McAuley DF, Urner M, Yarnell CJ, Goligher EC, Heath A. Chen Z, et al. Crit Care Explor. 2024 Sep 20;6(10):e1152. doi: 10.1097/CCE.0000000000001152. eCollection 2024 Oct 1. Crit Care Explor. 2024. PMID: 39302988 Free PMC article. - Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines.
Rufibach K, Beyersmann J, Friede T, Schmoor C, Stegherr R. Rufibach K, et al. Trials. 2024 May 31;25(1):353. doi: 10.1186/s13063-024-08186-7. Trials. 2024. PMID: 38822392 Free PMC article. - The times are changing: A primer on novel clinical trial designs and endpoints in critical care research.
Behal ML, Flannery AH, Miano TA. Behal ML, et al. Am J Health Syst Pharm. 2024 Sep 9;81(18):890-902. doi: 10.1093/ajhp/zxae134. Am J Health Syst Pharm. 2024. PMID: 38742701 No abstract available. - The Effect of New Acuity Circle Policy on Simultaneous Liver and Kidney Transplantation in the United States.
Okumura K, Dhand A, Misawa R, Sogawa H, Veillette G, Nishida S. Okumura K, et al. J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101296. doi: 10.1016/j.jceh.2023.10.007. Epub 2023 Oct 21. J Clin Exp Hepatol. 2024. PMID: 38544764
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical